ImmunityBio (IBRX) Aandelenoverzicht

ImmunityBio, Inc., een biotechnologiebedrijf, richt zich op het innoveren, ontwikkelen en op de markt brengen van de volgende generatie immuuntherapieën die zijn ontworpen om het immuunsysteem van de patiënt te activeren en duurzame bescherming te bieden tegen kanker en infectieziekten. Meer informatie

IBRX fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

Verhandeld tegen 80.3% onder onze schatting van de reële waarde

De winst zal naar verwachting met 63.26% per jaar groeien

Risicoanalyse

Negatief eigen vermogen

Zeer volatiele aandelenkoers in de afgelopen 3 maanden vergeleken met de US markt

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft minder dan 1 jaar cash runway

IBRX Community Fair Values

Create Narrative

See what 82 others think this stock is worth. Follow their fair value or set your own to get alerts.

ImmunityBio

AnalystConsensusTarget

Based on Analyst Price Targets

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?

View narrative

US$13.5

47.1% ondergewaardeerd

391

ImmunityBio

AnalystLowTarget

Community Contributor

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?

View narrative

US$11

35.1% ondergewaardeerd

ImmunityBio

AnalystHighTarget

Community Contributor

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?

View narrative

US$23

69.0% ondergewaardeerd

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

5.4k

106

US$21.53

66.9% ondergewaardeerd

stuart_roberts's

Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

ImmunityBio, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor ImmunityBio
Historische aandelenkoersen
Huidige aandelenkoers	US$7.14
52 Week Hoogtepunt	US$12.43
52 Week Laag	US$1.83
Bèta	-0.076
1 maand verandering	-31.61%
3 maanden verandering	260.61%
1 Jaar Verandering	134.10%
3 jaar verandering	327.54%
5 jaar verandering	-61.90%
Verandering sinds IPO	-81.55%

Recent nieuws en updates

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

Mar 18Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?

ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion

Mar 17

Recent updates

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion

Mar 17

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Mar 04Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?

Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 07

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Apr 29

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Mar 07

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 17

ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential

Dec 11

ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful

Oct 25

ImmunityBio: Moving The Needle

Oct 07

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Sep 21

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

Aug 14

ImmunityBio: All Eyes On Execution Now (Rating Upgrade)

Jul 09

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

Jun 25

Rendement voor aandeelhouders

	IBRX	US Biotechs	US Markt
7D	-11.5%	2.3%	-0.3%
1Y	134.1%	31.7%	16.1%

Rendement versus industrie: IBRX overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 31.7 % opleverde.

Rendement versus markt: IBRX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 16.1 %.

Prijsvolatiliteit

Is IBRX's price volatile compared to industry and market?
IBRX volatility
IBRX Average Weekly Movement	24.8%
Biotechs Industry Average Movement	11.3%
Market Average Movement	7.1%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.3%

Stabiele aandelenkoers: De aandelenkoers van IBRX is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van IBRX is het afgelopen jaar gestegen van 15% naar 25%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	688	Rich Adcock	immunitybio.com

ImmunityBio, Inc, een biotechnologiebedrijf, richt zich op het innoveren, ontwikkelen en commercialiseren van de volgende generatie immuuntherapieën die zijn ontworpen om het immuunsysteem van de patiënt te activeren en duurzame bescherming te bieden tegen kanker en infectieziekten. Het bedrijf heeft platforms voor de ontwikkeling van biologische producten en productkandidaten, waaronder cytokinefusie-eiwitten, DNA- en vaccinvectoren en celtherapieën. Het platform van het bedrijf heeft de eerste therapeutische middelen voor mensen voortgebracht die zullen worden onderzocht in klinische studies op vloeibare en vaste tumoren.

ImmunityBio, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van ImmunityBio zich tot de beurswaarde?
IBRX fundamentele statistieken
Marktkapitalisatie	US$7.92b
Inkomsten(TTM)	-US$351.40m
Inkomsten(TTM)	US$113.29m

65.1x

P/S-verhouding

-21.0x

Koers/Winstverhouding

Is IBRX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IBRX resultatenrekening (TTM)
Inkomsten	US$113.29m
Kosten van inkomsten	US$753.00k
Brutowinst	US$112.54m
Overige uitgaven	US$463.93m
Inkomsten	-US$351.40m

Laatst gerapporteerde inkomsten

Dec 31, 2025

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.34
Brutomarge	99.34%
Nettowinstmarge	-310.18%
Schuld/Eigen Vermogen Verhouding	-160.8%

Hoe presteerde IBRX op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/04/01 02:31
Aandelenkoers aan het einde van de dag	2026/04/01 00:00
Inkomsten	2025/12/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

ImmunityBio, Inc. wordt gevolgd door 8 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Justin Zelin	BTIG
Suranjit Mukherjee	BTIG
Jason Kolbert	D. Boral Capital LLC.

ImmunityBio (IBRX) Aandelenoverzicht

Beloningen

Risicoanalyse

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

Looking to be second time lucky with a game-changing new product

ImmunityBio, Inc. Concurrenten

Madrigal Pharmaceuticals

Krystal Biotech

Viridian Therapeutics

Syndax Pharmaceuticals

Prijsgeschiedenis en prestaties

Recent nieuws en updates

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA Plus BCG Versus BCG Alone

ImmunityBio, Inc. Announces Approval For ANKTIVA In Macau Sar China For Bcg-Unresponsive Nmibc With Cis ± Papillary Tumors

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion

Immunitybio Announces NCCN Clinical Practice Guidelines in Oncology Have Been Updated to Include Anktiva Plus BCG for Patients with BCG-Unresponsive NMIBC with Papillary-Only Disease

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from over 60 Healthy and Cancer Donors

Recent updates

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA Plus BCG Versus BCG Alone

ImmunityBio, Inc. Announces Approval For ANKTIVA In Macau Sar China For Bcg-Unresponsive Nmibc With Cis ± Papillary Tumors

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion

Immunitybio Announces NCCN Clinical Practice Guidelines in Oncology Have Been Updated to Include Anktiva Plus BCG for Patients with BCG-Unresponsive NMIBC with Papillary-Only Disease

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from over 60 Healthy and Cancer Donors

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

Forecast breakeven date moved forward to 2027

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

ImmunityBio, Inc. Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA®? Plus BCG Versus BCG Alone in BCG-Naive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

President exercised options and sold US$675k worth of stock

New major risk - Financial position

Full year 2025 earnings: EPS exceeds analyst expectations

ImmunityBio Receives Authorization from the European Commission for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

ImmunityBio, Inc. Reports Productive Regulatory Engagement with Saudi Food and Drug Authority At USA -Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

President exercised options and sold US$971k worth of stock

ImmunityBio, Inc. Launches Phase 2 Chemotherapy-FreeCAR-NK Cell Therapy Trial with Anktiva (ResQ215B) in Indolent Lymphomas

ImmunityBio, Inc. Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA Plus CAR-NK, Chemo-Free Therapy

Price target increased by 9.6% to US$11.40

Board Member notifies of intention to sell stock

Immunitybio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA in BCG-Unresponsive Papillary Bladder Cancer

Consensus estimates of losses per share improve by 10%

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

New minor risk - Share price stability

Saudi Fda Grants Accelerated Approval to ImmunityBio , Inc.'s Anktiva for Non-Muscle Invasive Bladder Cancer Witharcinoma In-Situ

ImmunityBio, Inc. Announces Positive Results Demonstrating ANKTIVA as a Lymphocyte Stimulating Agent in Combination with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Forecast to breakeven in 2028

ImmiBio, Inc. Announces Treatment with ANKTIVA®? (nogapendekin Alfa Inbakicept-pmln) Plus Bacillus Calmette-Guerin

ImmunityBio, Inc. Appoints Bruce Wendel to the Board, Effective December 12, 2025

Immunitybio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for Anktiva with Bcg for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

New minor risk - Financial position

Third quarter 2025 earnings: EPS exceeds analyst expectations

New minor risk - Profitability

ImmunityBio, Inc. Announces its ANKTIVA Reverses Lymphopenia and Extends Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

ImmunityBio, Inc. Announces Initial Data Shows 100% Disease Control in 5 Out of 5 Patients with Recurrent Glioblastoma with Two Patients in Near Complete Response Treated with Immunotherapy's ANKTIVA®?, NK Cell Therapy Plus Optune Gio®? Device

ImmunityBio, Inc. Announces Phase 2 Study of ANKTIVA®? in Patients with Long COVID

Price target decreased by 16% to US$10.20

Immunitybio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free

ImmunityBio, Inc. Announces Houston's Michael E. DeBakey Department of Veterans Affairs Medical Center Is Among the First VA Hospitals to Helpister ANKTIVA to Bladder Cancer Patients

No longer forecast to breakeven

Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

ImmunityBio, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield™ Platform, in Patients with Solid Tumors

First quarter 2025 earnings: EPS misses analyst expectations

ImmunityBio, Inc. Receives Refusal to File Letter from the U.S. Food and Drug Administration for the Supplemental Biologics License Application

ImmunityBio, Inc., Annual General Meeting, Jun 18, 2025

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

ImmunityBio, Inc. Announces Positive Long-Term Results from Its Quilt-3.032 Study of Anktiva® (Nogapendekin Alfa Inbakicept-Guerin) Plus BCG

New major risk - Shareholder dilution

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA to Treat Lymphopenia

ImmunityBio, Inc. has filed a Follow-on Equity Offering in the amount of $75.000001 million.

Pomerantz LLP and Holzer & Holzer, LLC Announces Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities

ImmunityBio, Inc. Announces First Dosing of Recombinant BCG in the U.S. and 60 Sites Are in the Process of Launching

Consensus revenue estimates decrease by 23%, EPS upgraded

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Price target decreased by 7.7% to US$11.25

New minor risk - Shareholder dilution